The posaconazole MIC 90 for 1,903 yeast isolates from France was 1 g/ml (range, <0.015 to 8 g/ml). Ninety percent of isolates with fluconazole MICs of >8 g/ml (n ‫؍‬ 509) and 90% of those with voriconazole MICs of >2 g/ml (n ‫؍‬ 80) were inhibited by 2 and 8 g/ml of posaconazole, respectively.
Yeasts, especially Candida spp., are among the most frequent causes of nosocomial bloodstream infections. Several non-albicans Candida spp. and rare species are often less susceptible to fluconazole (5) . Among the new antifungals available, posaconazole has emerged as the one with the broadest spectrum of in vitro activity against yeasts and filamentous and dimorphic fungi (8, 13) . Using the method standardized by the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST), we report here the in vitro susceptibility profiles to posaconazole of 1,903 yeast isolates.
( Active powders of known potency of posaconazole (Schering-Plough Research Institute, Kenilworth, NJ), fluconazole, and voriconazole (both from Pfizer Central Research, Sandwich, United Kingdom) were used. The final concentrations tested were 0.015 to 8 g/ml for posaconazole and voriconazole and 0.125 to 64 g/ml for fluconazole.
The MICs of posaconazole, fluconazole, and voriconazole were determined according to AFST-EUCAST discussion document 7.1 (12) . Quality control strains were included in each set. Since breakpoints have not yet been published, we used thresholds that defined 95% of the C. albicans isolates as susceptible and 98% of the C. krusei isolates as resistant to fluconazole. Thus, isolates were considered fluconazole resistant or susceptible when MICs were Ն8 g/ml or Յ4 g/ml, respectively. Likewise, an arbitrary threshold of Ն2 g/ml defined isolates with decreased susceptibility to voriconazole and posaconazole.
The overall susceptibilities to posaconazole, divided into those for yeast isolates from blood (n ϭ 1,383) and those for isolates from other sites (n ϭ 428), are reported in Table 1 for the 10 most frequently isolated species of our collection. The MIC 50 (range) value for the 1,535 Candida sp. isolates was 0.06 g/ml (Յ0.015 to Ն8 g/ml). Twenty-nine percent (74/254 isolates) of C. glabrata isolates exhibited posaconazole MICs of Ն2 g/ml. Considering the C. glabrata isolates with fluconazole MICs of Ն8 g/ml (n ϭ 230), 68% were inhibited by 1 g/ml of posaconazole and 83% were inhibited by 1 g/ml of voriconazole. Considering the C. glabrata isolates with voriconazole MICs of Ն2 g/ml (n ϭ 41), the posaconazole MIC 50 was Ն8 g/ml. For C. krusei, the activity of posaconazole was similar to that of voriconazole, although 3/50 isolates presented voriconazole MICs of Ն2 g/ml and remained inhibited by Յ1 g/ml of posaconazole. Table 2 summarizes the in vitro susceptibilities to posaconazole, in comparison to those to fluconazole and voriconazole, of 79 uncommon yeasts (i.e., at least 2 but less than 12 isolates per species). Posaconazole MICs were lower than the corresponding fluconazole MICs, and overall, voriconazole had equal or lower MICs than those of posaconazole. MICs for posaconazole against Rhodotorula spp. were lower than those of voriconazole. Yeast species with reduced intrinsic activity of fluconazole had higher posaconazole and voriconazole MICs, with the highest MICs of the three azoles tested being observed for C. haemulonii isolates.
Overall, considering the 1,903 isolates, comparative MIC 50 s (range) were 0.5 g/ml (Յ0.125 to Ն64 g/ml), Յ0.015 (Յ0.015 to Ն8 g/ml), and 0.125 (Յ0.015 to 8 g/ml) for fluconazole, voriconazole, and posaconazole, respectively, showing that posaconazole was more active than fluconazole, but slightly less active than voriconazole, against these clinical isolates. Table 3 shows the distribution of posaconazole MICs according to those of fluconazole or voriconazole for all isolates. There was a clear correlation (P Ͻ 0.0001) between posaconazole MICs and either fluconazole (R 2 ϭ 0.63) or voriconazole (R 2 ϭ 0.69) MICs. Considering isolates with fluconazole MICs of Յ4 g/ml (n ϭ 1,394), the posaconazole MIC 50 and MIC 90 were 0.06 and 0.25 g/ml, respectively, and for those with fluconazole MICs of Ն8 g/ml (n ϭ 509), the posaconazole MIC 50 and MIC 90 were 0.5 and 2 g/ml, respectively. Considering yeast isolates with voriconazole MICs of Յ1 g/ml (n ϭ 1,823), the posaconazole MIC 50 and MIC 90 were 0.06 and 1 g/ml, respectively, and for those with voriconazole MICs of Ն2 g/ml (n ϭ 80), the posaconazole MIC 50 and MIC 90 were 4 and 8 g/ml, respectively.
We report here the in vitro susceptibilities to posaconazole of 1,903 yeast isolates recently collected in France, mostly from blood, with a MIC 50 of 0.125 g/ml. In previous studies and here, clinical isolates of C. albicans and C. dubliniensis were the most susceptible species to posaconazole (1, 3, 5, 11, 14) . In considering C. glabrata isolates, the posaconazole MIC 90 values determined here were slightly higher than those reported elsewhere (1, 11) . Posaconazole was slightly less active than voriconazole against C. glabrata, as shown in at least two other studies (10, 11) . Cryptococcus neoformans isolates were highly susceptible to posaconazole, and slightly higher posaconazole MIC 50 values than those of voriconazole were found, in accordance with previous data for a smaller sample (1, 6, 11) . Interestingly, posaconazole was also active against several rare but potentially emerging yeast species known to be less susceptible to antifungals, including fluconazole. Few reports have emphasized that the activity of voriconazole is reduced against Candida sp. isolates with decreased susceptibility to fluconazole (2, 4, 9) . Cross-resistance between extended-spectrum azoles has been mentioned previously, especially for C. glabrata isolates. Indeed, Pfaller et al. reported that among fluconazole-resistant C. glabrata isolates, only 4% remained susceptible to posaconazole and 13% remained susceptible to voriconazole with a cutoff MIC of Յ1 g/ml for posaconazole and voriconazole (7) . In this study, we also evidenced such 
